TEST:

LiquidLung™

"IVBH...will unveil groundbreaking data from an independent validation study of the company's proprietary LiquidLung lung cancer detection technology, at the ASCO® 2023 Annual Meeting. This study of 3,744 subjects, including patients with pre-operative lung cancer and non-cancer controls, demonstrated accurate detection of early-stage lung cancer across prevalent histologic types and subgroups of patients with lung cancer, including never-smokers."